We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
Cap. Flow
-$329M
Cap. Flow %
-4.22%
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$254M
2
PFE icon
Pfizer
PFE
+$130M
3
CMPX icon
Compass Therapeutics
CMPX
+$71.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$64.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$61.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$156M
2
ELV icon
Elevance Health
ELV
+$77.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M
4
PGNY icon
Progyny
PGNY
+$71.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$68.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Industrials 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMIC
76
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$24.3M 0.31%
70,145
+3,528
+5% +$1.37M
SCPH
77
DELISTED
scPharmaceuticals
SCPH
$24.1M 0.31%
4,797,148
– –
JNCE
78
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$23.9M 0.31%
2,859,900
+204,300
+8% +$1.68M
KDNY
79
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$23.1M 0.3%
1,418,300
-2,337
-0.2% -$33.3K
DBTX
80
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$23M 0.3%
4,945,192
– –
HARP
81
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$21.9M 0.28%
290,351
+29,220
+11% +$1.99M
GILD icon
82
Gilead Sciences
GILD
$167B
$20.9M 0.27%
287,600
– –
APLT
83
DELISTED
Applied Therapeutics
APLT
$20.7M 0.27%
2,313,681
+56,294
+2% +$739K
XENE icon
84
Xenon Pharmaceuticals
XENE
$6.28B
$19.7M 0.25%
631,000
+154,000
+32% +$4.6M
LOGC
85
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$19.6M 0.25%
8,466,783
– –
LENZ
86
LENZ Therapeutics
LENZ
$184M
$19.5M 0.25%
223,687
+16,558
+8% +$1.37M
MRSN
87
DELISTED
Mersana Therapeutics
MRSN
$18M 0.23%
115,554
– –
CMMB
88
Chemomab Therapeutics
CMMB
$10.5M
$17.8M 0.23%
644,544
– –
DHR.PRB
89
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
– –
0
– –
CRIS icon
90
Curis
CRIS
$9.41M
$17.3M 0.22%
9,087
+283
+3% +$673K
ILMN icon
91
Illumina
ILMN
$29.2B
$17.2M 0.22%
+46,363
New +$17.6M
IRON icon
92
Disc Medicine
IRON
$2.85B
$17M 0.22%
194,207
– –
MIST icon
93
Milestone Pharmaceuticals
MIST
$133M
$16.9M 0.22%
2,583,821
– –
CRVS icon
94
Corvus Pharmaceuticals
CRVS
$1.12B
$16.7M 0.22%
6,943,654
– –
NXTC icon
95
NextCure
NXTC
$22.1M
$16.3M 0.21%
225,918
– –
CLDX icon
96
Celldex Therapeutics
CLDX
$2.79B
$15.7M 0.2%
406,100
-8,200
-2% -$357K
RXST icon
97
RxSight
RXST
$250M
$15.6M 0.2%
1,383,500
+133,500
+11% +$1.6M
LAB icon
98
Standard BioTools
LAB
$311M
$15M 0.19%
3,819,348
-780,223
-17% -$3.65M
SYBX
99
DELISTED
Synlogic
SYBX
$14.6M 0.19%
402,000
– –
ACRS icon
100
Aclaris Therapeutics
ACRS
$744M
$14.3M 0.18%
985,900
+334,117
+51% +$5.06M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2021 Portfolio in Review

As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.

Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.

  • OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
  • OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
  • OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
  • OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
  • OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
  • OrbiMed opened 13 new positions and closed 29 in Q4 2021.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.